Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)

ClinicalTrials.gov ID: NCT01470989

Public ClinicalTrials.gov record NCT01470989. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective

Study identification

NCT ID
NCT01470989
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
136 participants

Conditions and interventions

Interventions

  • ACZ885 Drug
  • Triamcinolone acetonide 40 mg Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2011
Primary completion
Apr 30, 2013
Completion
Apr 30, 2013
Last update posted
Jul 8, 2021

2011 – 2013

United States locations

U.S. sites
33
U.S. states
16
U.S. cities
31
Facility City State ZIP Site status
Novartis Investigative Site Anniston Alabama 36207-5710
Novartis Investigative Site Mobile Alabama 36608
Novartis Investigative Site Norwalk California 90650
Novartis Investigative Site Pasadena California 91105
Novartis Investigative Site San Diego California 92108
Novartis Investigative Site Tustin California 92780
Novartis Investigative Site Clearwater Florida 33756
Novartis Investigative Site Jupiter Florida 33458
Novartis Investigative Site Decatur Georgia 30035
Novartis Investigative Site Overland Park Kansas 66215
Novartis Investigative Site Topeka Kansas 66606
Novartis Investigative Site Wichita Kansas 67208
Novartis Investigative Site Metairie Louisiana 70006
Novartis Investigative Site Opelousas Louisiana 70570
Novartis Investigative Site Flint Michigan 48532
Novartis Investigative Site Troy Michigan 48085
Novartis Investigative Site Jackson Mississippi 39202
Novartis Investigative Site Jackson Mississippi 39209
Novartis Investigative Site Missoula Montana 59804
Novartis Investigative Site Omaha Nebraska 68114
Novartis Investigative Site Freehold New Jersey 07728
Novartis Investigative Site Hickory North Carolina 28602
Novartis Investigative Site Dayton Ohio 45402
Novartis Investigative Site Willoughby Hills Ohio 44094
Novartis Investigative Site Charleston South Carolina 29407
Novartis Investigative Site Charleston South Carolina 29412
Novartis Investigative Site Columbia South Carolina 29204
Novartis Investigative Site Varnville South Carolina 29944
Novartis Investigative Site Bristol Tennessee 37620
Novartis Investigative Site Clarksville Tennessee 37043
Novartis Investigative Site Johnson City Tennessee 37601
Novartis Investigative Site Danville Virginia 24541
Novartis Investigative Site Newport News Virginia 23606

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01470989, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 8, 2021 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01470989 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →